Weekly Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings on May 16, 2018

May 16, 2018 - By Jenna Rose

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Corporate Logo
During Q4 2017 the big money sentiment increased to 1.22. That’s change of 0.01, from 2017Q3’s 1.21. 19 investors sold all, 48 reduced holdings as Agios Pharmaceuticals, Inc. ratio is positive. 55 increased holdings while 27 funds acquired holdings. Funds hold 45.70 million shares thus 2.27% more from 2017Q3’s 44.69 million shares.
Metropolitan Life Insurance Company stated it has 0% of its capital in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). State Common Retirement Fund invested 0.01% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Amalgamated Savings Bank owns 8,287 shs. 45,122 were accumulated by Rhumbline Advisers. Teachers Retirement System Of The State Of Kentucky, a Kentucky-based fund reported 46,924 shs. Citadel Advisors Limited Liability Company has invested 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). The Colorado-based Alps Advisors has invested 0.02% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Manufacturers Life The holds 0% or 1,483 shs in its capital. Geode Mngmt Lc reported 369,512 shs or 0.01% of all its holdings. Pictet Asset Mgmt Limited invested 0.04% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Clearbridge Invests Lc reported 0.08% of its capital in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Hbk Invs L P stated it has 5,355 shs. Bnp Paribas Asset has 0.12% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). 49,300 are owned by Canada Pension Plan Investment Board. Fifth Third Bankshares holds 0% of its capital in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 155 shs.

Agios Pharmaceuticals, Inc. had 23 sales and 1 insider purchase since January 10, 2018. This’s net activity of $18.55 million. On Thursday, February 22 the insider Hoerter Steven L. sold $161,192. 3,000 shs were sold by Biller Scott, worth $225,607. Shares for $170,190 were sold by Bowden Christopher on Thursday, April 12. On Monday, March 19 $557,396 worth of stock was sold by Foster-Cheek Kaye I. Scadden David bought $16,688 worth of stock or 200 shs. 2,150 shs were sold by Alenson Carman, worth $161,250 on Friday, January 12.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Coverage

In total 4 analysts cover Agios Pharma (NASDAQ:AGIO). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. (NASDAQ:AGIO) has 100% bullish analysts. 5 are the (NASDAQ:AGIO)’s ratings reports on May 16, 2018 according to StockzIntelligence Inc. The company rating was maintained by Credit Suisse on Thursday, February 15. On Sunday, November 19 SunTrust maintained Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) with “Buy” rating. On Wednesday, April 11 the firm has “Outperform” rating given by Credit Suisse. On Wednesday, February 14 the stock has “Buy” rating by RBC Capital Markets. In Thursday, February 15 report JP Morgan maintained the stock with “Overweight” rating. Listed here are Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) PTs and latest ratings.

11/04/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $80 New Target: $95 Maintain
15/02/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $76 New Target: $85 Maintain
15/02/2018 Broker: Credit Suisse Rating: Buy New Target: $80.0 Maintain
14/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $88.0 Maintain
19/11/2017 Broker: SunTrust Rating: Buy New Target: $80.0 Maintain

Ticker’s shares touched $86.23 during the last trading session after 0.92% change.Agios Pharmaceuticals, Inc. has volume of 53,492 shares. Since May 16, 2017 AGIO has risen 41.40% and is uptrending. AGIO outperformed by 29.85% the S&P500.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States.The firm is worth $4.97 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML.Last it reported negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

For more Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news brought out recently go to: Streetinsider.com, Seekingalpha.com, Nasdaq.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Agios Pharma (AGIO) PT Raised to $90 at RBC Capital” brought out on May 07, 2018, “Agios Pharmaceuticals’ (AGIO) CEO David Schenkein on Investor Day 2018 Results – Earnings Call Transcript” on May 06, 2018, “Agios Announces Revised Starting Time of 8:00am ET for Investor Day and First Quarter 2018 Financial Results …” with a publish date: April 27, 2018, “Agios Pharmaceuticals (AGIO) Investor Presentation – Slideshow” and the last “A Fresh Look At Celgene After Q1 And New Info On Ozanimod” with publication date: May 08, 2018.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.